Arcutis Biotherapeutics evp Masaru Matsuda sells $1.37M in planned share sale

Masaru Matsuda, Executive Vice President and Chief Legal Officer at Arcutis Biotherapeutics, sold 40,000 shares of common stock on November 4, 2026, to the tune of $1,372,672. The price per share ranged from $34.00 to $37.7966. This share sale was part of a pre-established 10b5-1 trading plan, which Matsuda had approved on June 5, 2026.

The transaction occurred as the stock was trading near its 52-week high of $34.80, following a 45% gain over the past six months. Projections suggest the stock is currently fairly valued. On November 2, Matsuda sold 1,219 shares of Arcutis Biotherapeutics common stock to satisfy tax withholding obligations for Restricted Stock Units, amounting to $38,841.

These shares were sold at prices ranging from $31.57 to $32.23. Prior to the larger November 4 sale, Matsuda purchased 40,000 shares by exercising stock options at $3.64 per share, for a total of $145,600. This option exercise was also governed by the same 10b5-1 plan. Matsuda now holds 111,289 shares of Arcutis Biotherapeutics common stock.

For those interested in ARQT's valuation and growth potential, InvestingPro provides extensive analysis, including 15 ProTips and a Pro Research Report. Meanwhile, Arcutis Biotherapeutics reported stronger-than-expected earnings for Q3 2026, with revenue of $143.9 million, exceeding the forecast of $141.94 million. However, the company missed profit expectations, reporting adjusted earnings of $0.06 per share against the estimated $0.18 per share.

This earnings shortfall led to a negative market reaction. The dermatology-focused firm attributes its revenue growth, which increased by 45% year-over-year, to persistent demand for its product, ZORYVE. Despite this growth, heavy expenditures continue to weigh on profitability. Analysts have yet to issue updated ratings following the financial results.